spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  glatiramer 

 HSMN NewsFeed - 19 Aug 2020
Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera(R)
Biopharmaceuticals Generics Neurology Product Launch
 HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 10 Apr 2018
Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 13 Feb 2018
Sandoz announces US FDA approval and launch of Glatopa(R) 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 28 Sep 2015
Teva Announces Approval of COPAXONE(R) in Japan for the Prevention of Relapse of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 3 Aug 2015
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Jan 2014
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE(R) (glatiramer acetate injection) 40mg/mL
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 4 Oct 2013
New TECFIDERA(R) (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Oct 2012
New Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Aug 2012
Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jun 2012
Teva Announces Favorable Court Ruling in COPAXONE(R) Patent Infringement Litigation
Biopharmaceuticals Generics Neurology Litigation
 HSMN NewsFeed - 20 May 2011
European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 11 Apr 2011
Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 7 Sep 2010
Court Denies Sandoz/Momenta's Summary Judgment of Invalidity in Copaxone(R) Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 30 Aug 2010
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 7 Jun 2010
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Jun 2010
Teva Announces Positive Results from a Study Assessing a New Formulation of Copaxone(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Feb 2010
Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Sep 2009
COPAXONE(R) Significantly Reduced Disease Severity in Long-Term Treated Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Apr 2009
Long-Term Study with COPAXONE Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Feb 2009
COPAXONE(R) is Approved for Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 18 Sep 2008
Longest Prospective Study in MS Confirmed Robust Clinical Benefits and Safety of COPAXONE(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Sep 2008
Betaseron(R) to Offer the Thinnest Needle in Multiple Sclerosis
Biopharmaceuticals Drug Delivery Neurology
 HSMN NewsFeed - 11 Jul 2008
Teva Comments on Paragraph IV Filing for COPAXONE(R); Intends to File Lawsuit against Generic Filer for Patent Infringement
Biopharmaceuticals Generics Neurology FDA Litigation
 HSMN NewsFeed - 11 Jul 2008
Momenta Pharmaceuticals Announces Filing of Abbreviated New Drug Application With a Paragraph IV Certification for Generic Version of Copaxone
Biopharmaceuticals Generics Neurology FDA
 HSMN NewsFeed - 10 Apr 2008
COPAXONE(R) Significantly Reduced Annual Relapse Rates and Stabilized Disease Progression in Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Mar 2008
Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Dec 2007
Early Treatment with COPAXONE(R) Demonstrated Robust Protection against Progression to Clinically Definite Multiple Sclerosis in the PreCISe Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Oct 2007
New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Oct 2007
Study Showed Patients Using COPAXONE(R) Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif(R) in Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Oct 2007
COPAXONE(R) Significantly Decreases Disease Activity in Patients Who Switched from Interferon Beta (IFNb) Due to Development of Neutralizing Antibodies (NAbs)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Oct 2007
Long-Term Study Shows COPAXONE(R) Significantly Slows Progression of Disability and Reduces Relapse Rates in Patients with Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 6 Jun 2007
COPAXONE(R) Pre-Filled Syringe Can Now Be Stored for up to One Month at Room Temperature
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 4 May 2007
Treatment with COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 May 2007
COPAXONE(R) Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Apr 2007
Data Published in Neurology Showed That Higher Dose of COPAXONE(R) Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Apr 2007
New One-Year Pharmacoeconomic Study Shows AVONEX(R) is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Apr 2007
First Pharmacoeconomic Analysis with Long-Term Data Showed COPAXONE(R) Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Feb 2007
Post-Hoc Data Analyses Published in Annals of Neurology Found COPAXONE(R) Significantly Delayed Accumulated Disability in Male Patients with Primary Progressive Multiple Sclerosis (PPMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 Jan 2007
Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Oct 2006
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2006
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
Study Showed Significant and Sustained Efficacy Of COPAXONE(R) Alone Following Short-Term Combination Therapy With IV Steroids in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 May 2006
COPAXONE(R) Reduced Relapses and Stabilized Disability as Measured by Expanded Disability Status Scale, When Avonex(R) Failed
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 May 2006
Long-Term Copaxone(R) Study Showed 92% of Multiple Sclerosis Patients Were Still Walking Unaided After a Mean of 10 Years on Treatment
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
glatiramer
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.